Abeona Therapeutics Inc (ABEO) Institutional Investor Snapshot (130 Funds, Q2 2026)

ABEO ranks #4007 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

130 institutions disclose a position in ABEO, but none treat it as a major bet — even Propel Bio Management, LLC, its most concentrated holder, allocates just 3.2% of its own portfolio to it.

ABEO is down 4.7% today, but institutions show net buying of $10.6M this quarter — a divergence between today's price move and the underlying institutional flow.

ABEO reported a net loss of $62.9M over the trailing twelve months.

• Not yet profitable — net loss of $62.9M over the trailing twelve months
• Revenue grew 554.4% year over year
• Net income declined year over year, from $57.2M to -$62.9M
• Operating cash flow was negative, using $76.3M in cash
• Current ratio of 6.93x — enough short-term assets to cover short-term liabilities
• Liabilities run 109.73x equity — a highly leveraged balance sheet worth noting